rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2006-8-16
|
pubmed:abstractText |
N-terminal pro-B-type natriuretic peptide (NT-proBNP) appears to be a strong risk marker of mortality in patients with acute coronary syndrome. However, little information is available on NT-proBNP as a predictor of long-term serious cardiovascular events beyond that of left ventricular ejection fraction in patients with acute myocardial infarction (AMI), most of them treated with an early invasive strategy and on a uniform optimal secondary preventive medication including long-term beta-adrenergic receptor blockade.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0008-6312
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel.
|
pubmed:issnType |
Print
|
pubmed:volume |
106
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
102-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16636540-Adrenergic beta-Antagonists,
pubmed-meshheading:16636540-Adult,
pubmed-meshheading:16636540-Age Factors,
pubmed-meshheading:16636540-Aged,
pubmed-meshheading:16636540-Aged, 80 and over,
pubmed-meshheading:16636540-Female,
pubmed-meshheading:16636540-Humans,
pubmed-meshheading:16636540-Male,
pubmed-meshheading:16636540-Middle Aged,
pubmed-meshheading:16636540-Myocardial Infarction,
pubmed-meshheading:16636540-Natriuretic Peptide, Brain,
pubmed-meshheading:16636540-Peptide Fragments,
pubmed-meshheading:16636540-Randomized Controlled Trials as Topic,
pubmed-meshheading:16636540-Risk Assessment
|
pubmed:year |
2006
|
pubmed:articleTitle |
N-terminal pro-B-type natriuretic peptide in risk stratification after acute myocardial infarction in patients on long-term beta-adrenergic receptor blocker therapy.
|
pubmed:affiliation |
Department of Cardiology,Ullevaal University Hospital, Oslo, Norway.
|
pubmed:publicationType |
Journal Article
|